PE20040750A1 - Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 - Google Patents

Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3

Info

Publication number
PE20040750A1
PE20040750A1 PE2003001156A PE2003001156A PE20040750A1 PE 20040750 A1 PE20040750 A1 PE 20040750A1 PE 2003001156 A PE2003001156 A PE 2003001156A PE 2003001156 A PE2003001156 A PE 2003001156A PE 20040750 A1 PE20040750 A1 PE 20040750A1
Authority
PE
Peru
Prior art keywords
17beta
aryl
isopropilpiperazin
benzidril
acetylpiperidin
Prior art date
Application number
PE2003001156A
Other languages
English (en)
Inventor
Kamil Paruch
Timothy Guzi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040750A1 publication Critical patent/PE20040750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE X ES CH, N; Z ES O, N(R6); R1 Y R2 SON ARILO, HETEROARILO, ARALQUILO, HETEROARALQUILO SUSTITUIDOS O NO CON HALO, ALQUILO, ARILO, ENTRE OTROS; R3 ES H, -OR6 CON LA CONDICION CUANDO X ES N, R3 NO ES -OR6; R4 ES H, ALQUILO, ARILO, CICLOALQUILO, ARALQUILO, ENTRE OTROS; m ES 0-4; R5 ES -C(O)R7, S(O2)R7; R6 ES H, ALQUILO, ARILO, HETEROARILO, ARALQUILO, ENTRE OTROS; R7 ES ALQUILO, ARILO, HETEROARILO, ARALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS EL GRUPO DE FORMULA a, b ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE COMPUESTOS INHIBIDORES DE 17BETA-HIDROXIESTEROIDE DESHIDROGENASA DE TIPO 3 PARA EL TRATAMIENTO DE ENFERMEDADES QUE DEPENDE DE ANDROGENOS
PE2003001156A 2002-11-18 2003-11-14 Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 PE20040750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42726302P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
PE20040750A1 true PE20040750A1 (es) 2004-11-06

Family

ID=32326512

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001156A PE20040750A1 (es) 2002-11-18 2003-11-14 Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3

Country Status (17)

Country Link
US (2) US7074795B2 (es)
EP (1) EP1562901B1 (es)
JP (2) JP4614770B2 (es)
CN (1) CN100374421C (es)
AR (1) AR042046A1 (es)
AT (1) ATE469886T1 (es)
AU (1) AU2003290799A1 (es)
CA (1) CA2506290C (es)
CL (1) CL2003002356A1 (es)
DE (1) DE60332862D1 (es)
ES (1) ES2345146T3 (es)
HK (1) HK1073313A1 (es)
MX (1) MXPA05005360A (es)
MY (1) MY130792A (es)
PE (1) PE20040750A1 (es)
TW (1) TW200412964A (es)
WO (1) WO2004046111A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60323765D1 (de) 2002-12-17 2008-11-06 Schering Corp Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
WO2012148174A2 (ko) * 2011-04-25 2012-11-01 Park Jun-Hyoung 탈모방지 및 발모촉진용 외용제 조성물
WO2014207309A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
WO2014207311A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1
SG11201510251TA (en) 2013-06-25 2016-01-28 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド １７β−ＨＳＤ１−阻害剤のプロドラッグ
JP6545266B2 (ja) 2014-12-23 2019-07-17 フォレンド ファーマ リミテッド １７β‐ＨＳＤ１抑制剤のプロドラッグ
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CN115716860A (zh) 2017-06-08 2023-02-28 佛恩多制药有限公司 15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮及17-肟
MX2020006219A (es) * 2017-12-15 2020-12-03 Inthera Bioscience AG Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
KR20210114390A (ko) 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594309B2 (en) 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
ES2077675T3 (es) 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
CA2062792C (en) 1989-07-07 2006-03-21 Fernard Labrie Treatment of androgen-related diseases
KR920703063A (ko) 1989-07-07 1992-12-17 원본미기재 양성 전립선 비대증의 예방 및/ 또는 치료를 위한 복합요법
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1994026767A1 (en) 1993-05-17 1994-11-24 Endorecherche Inc. Improved antiandrogens
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
CA2266015C (en) * 1996-09-13 2003-12-30 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
CA2323089A1 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use
PT1423381E (pt) 2001-09-06 2007-04-30 Schering Corp Inibidores de 17-b-hidroxiesteróide-desidrogenase do tipo 3 para o tratamento de doenças dependentes de androgénio
EP1436281B1 (en) * 2001-10-17 2010-06-16 Schering Corporation Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Also Published As

Publication number Publication date
US20040127503A1 (en) 2004-07-01
CL2003002356A1 (es) 2005-02-11
JP4614770B2 (ja) 2011-01-19
AR042046A1 (es) 2005-06-08
WO2004046111A1 (en) 2004-06-03
TW200412964A (en) 2004-08-01
AU2003290799A1 (en) 2004-06-15
CN1738800A (zh) 2006-02-22
MY130792A (en) 2007-07-31
ES2345146T3 (es) 2010-09-16
US7476681B2 (en) 2009-01-13
CA2506290C (en) 2012-04-24
MXPA05005360A (es) 2005-08-03
CA2506290A1 (en) 2004-06-03
EP1562901A1 (en) 2005-08-17
JP2010138204A (ja) 2010-06-24
CN100374421C (zh) 2008-03-12
US7074795B2 (en) 2006-07-11
US20060148816A1 (en) 2006-07-06
JP2006513169A (ja) 2006-04-20
EP1562901B1 (en) 2010-06-02
HK1073313A1 (en) 2005-09-30
ATE469886T1 (de) 2010-06-15
DE60332862D1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
SE0300956D0 (sv) Stabilisatorblandningar
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
CO4960641A1 (es) Derivados de piperidina 1,4-disustituida conteniendo fluor
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
PE20040666A1 (es) Derivados novedosos de piperidina
BR0309558A (pt) Derivados de quinazolina e medicamentos
ATE482933T1 (de) Sulfopyrrolderivate
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
BR0315837A (pt) Derivados de amida de ácido heteroaril-hexanóico como agentes imunomoduladores
NO20051028L (no) Substituerte tiaziner som materialbeskyttelsesmidler
RS115804A (en) Pyrrolidine derivatives as oxytocin antagonists
DK0732332T3 (da) Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf
CO5180541A1 (es) Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed